Thursday, 28 August 2008, from 10:30 to 12:00, Room C
With Doug Bettcher, Laurent Huber, S Subramanian, A Blanco, JG Park, J Samet
Movement for a global treaty to control tobacco: FCTC and beyond
WHO’s top priority: Doug Bettcher
Role of civil society: Laurent Huber
Accelerating the framework convention : Russia S Subramanian
Tobacco control in Latin America: A Blanco
The post-FCTC era: JG Park
Thursday, 28 August, 14:15 - 15-15 Room G
Tobacco dependence and smoking cessation
A randomized controlled trial of nicotine replacement therapy for low-income smokers: C. Miller
A cross-sectional study on nicotine dependence of adult smokers in seven cities of China: G. Feng
International lessons learned from stop smoking campaigns: K. Gutierrez
Thursday, 28 August, 15:30-16:30 Room I
Pascal Diethelm, Luk Joossens, M. Potschke-Langer, Tapani Piha, L Sanda
Tobacco control in Europe
Overview of tobacco control policies in Europe and introducing tobacco control scale: Luk Joossens
Is Germany moving? M. Potschke-Langer
The Balkans: L Sanda
Making progress in tobacco control in the European Union: Tapani Piha
Thursday, August 28, 17:00 - 18:30 Room E
E. Blecher (South
Africa), K. Bao Giang (Vietnam), R. Ben Zid (Tunisia), M. Baquilod
(Philippines), A. Ahsan (Indonesia), S. Lutnaes (Norway)
The economic impact of tobacco: myth and reality
Are cigarettes becoming less affordable? Evidence from 78 countries since 1990: E. Blecher
Impact of tobacco growing on the livelihood and health of tobacco farmers, and the environment: K. Bao Giang
Finding alternatives to tobacco growing: R. Ben Zid
Household expenditure and tobacco use in the Philippines: M. Baquilod
The impact of increasing the cigarette tax on the Indonesian economy: input-output analysis 2003: A. Ahsan
Norwegian public funds invested in the tobacco industry: S. Lutnaes
Making progress in tobacco control in the European Union: Tapani Piha
My question:
Whilst diseases are being investigated in order to minimize their impact and eventually do away with them, pharmaceutical products are being developed and prescribed in order to cure/alleviate such diseases.
Nowadays, smoking cessation is being increasingly approached through pharmaceutical products. An epidemic (smoking) is thus maintained (because of its profitability to governments?) while providing pharmaceutical products - in some cases (partly) refunded by governments - thereby creating a medically "caring" environment.
Isn't this a perverse perpetuum mobile attitude rather than progress?
Posted by: Sonja Vanhove-Deneve, Smoking Cessation Counselor Belgium | July 29, 2008 at 03:05 AM
About WHO's top priority: What is it level of active smokers adults and teenagers?
Posted by: Miss Nancy P. Hachen | August 11, 2008 at 12:23 PM
Regarding the dependence of snuff and smoking cessation: International lessons learned from campaigns quitting ... what are the lessons??
Posted by: Miss Nancy P. Hachen | August 11, 2008 at 12:30 PM